Impressions on the Trial of "Maintenance"/Early 2nd Line Alimta vs. Placebo

Article

A couple of weeks ago I described in a prior post the design and general results of a trial coded as JMEN by the sponsor company, Eli Lilly. This study randomized patients to either maintenance/early second line alimta (pemetrexed) or a placebo after four cycles of initial platinum-based doublet chemo with a drug other than alimta.

Subscribe to placebo